Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Hawkins RD, Hon GC, Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet. 2010;11:476–486.
   PubMed Web of Science ®Google Scholar
• Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15:353–365.
   PubMed Web of Science ®Google Scholar
• Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009;85:142–154.
   PubMed Web of Science ®Google Scholar
• Anderson MW, Schrijver I. Next generation DNA sequencing and the future of genomic medicine. Genes (Basel). 2010;1:38–69.
   PubMed Web of Science ®Google Scholar
• Schram AM, Reales D, Galle J, et al. Oncologist use and perception of large panel next-generation tumor sequencing. Ann Oncol. 2017;28:2298–2304.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). Considerations for design, development, and analytical validation of next generation sequencing-based in vitro diagnostics intended to aim in the diagnosis of suspected germline diseases. [updated 2018 Apr 13]. Available from: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM509838.pdf
   Google Scholar
• Froyen G, Le Mercier M, Lierman E, et al. Standardization of somatic variant classifications in solid and haematological tumours by a two-level approach of biological and clinical classes: an initiative of the belgian ComPerMed expert panel. Cancers (Basel). 2019;11:2030.
   PubMed Web of Science ®Google Scholar
• Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. J Cin Oncol Precis Oncol. 2018.
   Web of Science ®Google Scholar
• Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4–23.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Weisburd B, Thomas B, et al.; The Exome Aggregation Consortium. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 2017;45:D840–D845.
   PubMed Web of Science ®Google Scholar
• , Auton A, Brooks LD, Durbin RM, et al.; 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68–74.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. J Cin Oncol Precis Oncol. 2017.
   Web of Science ®Google Scholar
• Tenaerts P, Madre L, Archdeacon P, et al. The Clinical Trials Transformation Initiative: innovation through collaboration. Nat Rev Drug Discov. 2014;13:797–798.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
   PubMed Web of Science ®Google Scholar
• Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437:376–380.
   PubMed Web of Science ®Google Scholar
• van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of next-generation sequencing technology. Trends Genet. 2014;30:418–426.
   PubMed Web of Science ®Google Scholar
• McKenzie AJ, Dilks H, Jones SF, et al. Should next-generation sequencing tests be performed on all cancer patients? Expert Rev Mol Diagn. 2019;19:89–93.
   PubMed Web of Science ®Google Scholar
• Al-Kateb H, Nguyen TT, Steger-May K, et al. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9:1737–1743.
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–713.
   PubMed Web of Science ®Google Scholar
• Stockley TL, Oza AM, Berman HK, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016;8:109.
   PubMed Web of Science ®Google Scholar
• Moorcraft SY, Gonzalez de Castro D, Cunningham D, et al. Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Ann Oncol. 2018;29:230–236.
   PubMed Web of Science ®Google Scholar
• Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7:586–595.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord JP, Gonçalves A, et al.; SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334.
   PubMed Web of Science ®Google Scholar
• Tran B, Brown AM, Bedard PL, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer. 2013;132:1547–1555.
   PubMed Web of Science ®Google Scholar
• Moore DA, Balbi K, Arkenau HT, et al. Routine use of a modest next generation sequencing panel provides additional clinically useful data beyond single gene testing in non-small cell lung cancer and is fit for purpose as a clinical assay: collated data from a single molecular diagnostic laboratory. J Cin Oncol. 2018;36:8540–8540.
   Web of Science ®Google Scholar
• Goswami RS, Luthra R, Singh RR, et al. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. Am J Clin Pathol. 2016;145:222–237.
   PubMed Web of Science ®Google Scholar
• Morris SM, Subramanian J, Gel ES, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018;13:e0196556.
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–D947.
   PubMed Web of Science ®Google Scholar
• Ree AH, Russnes HG, Heinrich D, et al. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017;2:e000158.
   PubMed Web of Science ®Google Scholar
• Ree AH, Nygaard V, Boye K, et al. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncol. 2020;59:733–740.
   PubMed Web of Science ®Google Scholar